Literature DB >> 24552124

Ambivalence in emotion-focused therapy for depression: the maintenance of problematically dominant self-narratives.

António P Ribeiro1, Inês Mendes, William B Stiles, Lynne Angus, Inês Sousa, Miguel M Gonçalves.   

Abstract

OBJECTIVE: Ambivalence can be understood as a cyclical movement between an emerging narrative novelty-an Innovative Moment (IM)-and a return to a problematically dominant self-narrative. The return implies that the IM, with its potential for change is devalued right after its emergence. Our goal is to test the hypothesis that the probability of the client expressing such form of ambivalence decreases across treatment in good-outcome cases but not in poor-outcome cases.
METHOD: Return-to-the-Problem Markers (RPMs) signaling moments of devaluation of IMs were coded in passages containing IMs in six clients with major depression treated with emotion-focused therapy: three good-outcome cases and three poor-outcome cases.
RESULTS: The percentage of IMs with RPMs decreased across therapy in good-outcome cases, whereas it remained unchanged and high in the poor-outcome cases.
CONCLUSIONS: These results were consistent with the theoretical suggestion that therapeutic failure may be associated with this form of ambivalence.

Entities:  

Keywords:  ambivalence; experiential/existential/humanistic psychotherapy; narrative; process research

Mesh:

Year:  2014        PMID: 24552124     DOI: 10.1080/10503307.2013.879620

Source DB:  PubMed          Journal:  Psychother Res        ISSN: 1050-3307


  2 in total

1.  Ambivalence Predicts Symptomatology in Cognitive-Behavioral and Narrative Therapies: An Exploratory Study.

Authors:  Cátia Braga; António P Ribeiro; Inês Sousa; Miguel M Gonçalves
Journal:  Front Psychol       Date:  2019-05-29

Review 2.  A review of cognitive conflicts research: a meta-analytic study of prevalence and relation to symptoms.

Authors:  Adrián Montesano; María Angeles López-González; Luis Angel Saúl; Guillem Feixas
Journal:  Neuropsychiatr Dis Treat       Date:  2015-12-04       Impact factor: 2.570

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.